Touchlight’s cell-free DNA platform offers a fundamentally different approach to DNA manufacturing—enabling the rapid, scalable, and high-quality production of enzymatically produced DNA for advanced therapies. At the core of this…
Read More
Touchlight’s Chief Scientific Officer, Dr. Jill Makin, discusses how the rapid evolution of advanced therapeutics is reshaping the industry, and why cell‑free DNA is has emerged as a foundational technology…
Read More
As cell and gene therapy scales, DNA choice matters. Learn the advantages of cell‑free DNA vs pDNA in this Q&A with Touchlight’s CSO.
Read More
This application note presents a comparative study of enzymatically manufactured doggybone DNA™ (dbDNA™) versus traditional plasmid DNA (pDNA) for lentiviral vector (LVV) production, using the FuGENE® 4K transfection reagent. The…
Read More
Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time,…
Read More
Reducing Lentiviral Vector Manufacturing Timelines with dbDNA™ Lentiviral vectors are essential for some of today’s most transformative cell and gene therapies, from CAR-T to modified stem cell treatments. But…
Read More
How AI Assisted Bioprocessing Can Transform Biotech Biotechnology is evolving, but some methods haven’t caught up. Slow experiments, costly materials, and outdated assumptions are holding back innovation. As demand…
Read More
This application note highlights the advantages of dbDNA™, a linear, enzymatically amplified DNA construct, as a cell-free alternative to plasmid DNA (pDNA) for lentiviral vector (LVV) production. Manufactured under GMP…
Read More
This article explores how Touchlight’s enzymatically amplified linear dbDNA™ technology overcomes the limitations of traditional plasmid-based methods in lentiviral vector (LVV) manufacturing. By optimizing vector design and transfection conditions, the…
Read More
As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) remains a limiting factor, slowed by scalability challenges, bacterial contamination…
Read More
